Vietnam Oncology Drugs Market Report 2022 to 2030

Vietnam Oncology Drugs Market Analysis

$ 3999

By 2030, it is anticipated that the Vietnam oncology drugs market will reach a value of $xx Mn from $982.2 Mn in 2022, growing at a CAGR of xx% during 2022-30. The oncology drugs market in Vietnam is dominated by a few domestic pharmaceutical companies such as Vimedimex Medi-Pharma, OPC Pharmaceutical, and Hanoi Pharmaceutical. The oncology market in Vietnam is segmented into different therapeutic areas and different treatment types. The major factors affecting the Vietnam oncology drugs market are the increasing disease burden of non-communicable diseases like cancer and the lack of healthcare facilities for cancer treatment in most areas of Vietnam.

ID: IN10VNPH018 CATEGORY: Pharmaceuticals GEOGRAPHY: Vietnam AUTHOR: Dr. Vishwa Modhia

Buy Now

Vietnam Oncology Drugs Market Analysis Summary

By 2030, it is anticipated that the Vietnam oncology drugs market will reach a value of $xx Mn from $982.2 Mn in 2022, growing at a CAGR of xx% during 2022-30.

Vietnam is a lower middle-income, developing country located in Southeastern Asia bordering the Gulf of Thailand, the Gulf of Tonkin, and the South China Sea. The Vietnamese government has emphasized the importance of cancer identification and prevention. This has included expanding cancer screening services and encouraging people to live healthier lifestyles. Vietnam's government spends 4.7 % of its GDP on healthcare.

vietnam oncology drugs market analysis

Market Dynamics

Market Growth Drivers Analysis

Targeted therapies, which are designed to directly target cancer cells while harming healthy cells as little as possible, are becoming more frequent in cancer treatment. This trend may be seen in Vietnam, where a growing number of targeted cancer treatments are being approved and prescribed. Cancer is becoming more common in Vietnam, with the National Cancer Institute predicting that the number of cancer cases will more than quadruple by 2030. This has boosted the demand for oncology medications. Vietnam has a thriving economy with one of the region's fastest growth rates. Vietnam also has a vast worker pool and low labour expenses, making doing business easier. These aspects could boost Vietnam's oncology drugs market.

Market Restraints

The healthcare industry in Vietnam is highly regulated, with stringent licencing, registration, and compliance requirements. This can hinder competition by creating obstacles to entry for new enterprises. Many people in Vietnam lack complete health insurance coverage, which limits their capacity to pay for healthcare services and creates financial issues for healthcare providers. These factors may deter new entrants into the Vietnam oncology drugs market.

Competitive Landscape

Key Players

Hanoi Pharmaceutical (VNM)
OPC Pharmaceutical (VNM)
Vimedimex Medi-Pharma (VNM)
Hoffmann-La Roche Ltd.
Novartis AG
Gilead Sciences Inc
Bayer AG

Healthcare Policies and Reimbursement Scenarios

The Drug Administration of Vietnam (DAV), which is part of the Ministry of Health, is the regulatory organisation in charge of cancer drug licencing and regulation in Vietnam. Based on clinical trial results, the agency evaluates the safety, efficacy, and quality of oncology medications and requires manufacturers to disclose thorough information about the drug's composition, manufacturing process, and packaging. Furthermore, the National Institute of Drug Quality Control (NIDQC) regulates oncology medications in Vietnam. The NIDQC is a government-funded organisation that performs drug testing and quality control, especially oncology medications.

The Ministry of Health (MOH) in Vietnam oversees the usage and reimbursement of pharmaceuticals, especially oncology drugs. The Ministry of Health maintains a list of essential pharmaceuticals that are approved for use in the public healthcare system, and some of these drugs may be offered free or at a reduced cost to qualified patients through the government's healthcare programmes. Private health insurance carriers in Vietnam may give coverage for cancer drugs to patients who are not eligible for government healthcare programmes or who require drugs that are not available in the public healthcare system.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Oncology Drugs Market Segmentation

By Drug class

Cytotoxic drugs
- Alkylating agents
- Antimetabolites
- Others
Targeted drugs
- Monoclonal antibodies
- Others
Hormonal drugs
Others

By Therapy

Chemotherapy
Targeted therapy
Immunotherapy

By Indication

Lung cancer
Stomach cancer
Colorectal cancer
Breast cancer
Prostate cancer
Others

By Dosage form

Solid
- Tablets
- Capsules
Liquid
Injectable
- Prefilled syringes
- Others

By Distribution channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.